Comparative Pharmacology
Head-to-head clinical analysis: ALBENZA versus VERMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBENZA versus VERMOX.
ALBENZA vs VERMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albendazole is a benzimidazole carbamate that inhibits tubulin polymerization by binding to the colchicine site of β-tubulin, disrupting microtubule formation. This leads to impaired uptake of glucose and depletion of glycogen stores, resulting in immobilization and death of susceptible helminths.
Binds to β-tubulin in parasitic cells, inhibiting microtubule polymerization, thereby impairing glucose uptake and causing energy depletion and parasite death.
400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis.
Mebendazole 100 mg orally twice daily for 3 days for pinworm, whipworm, hookworm, and roundworm infections. For pinworm, may repeat after 2 weeks. For hookworm and whipworm, may require longer courses.
None Documented
None Documented
Terminal elimination half-life of albendazole sulfoxide (active metabolite) is 8-12 hours; albendazole itself has a very short half-life (<1 hour) due to extensive first-pass metabolism.
2-8 hours (terminal half-life, may be prolonged in hepatic impairment or obstruction)
Primarily biliary/fecal (less than 2% renal as unchanged drug and metabolites; most eliminated via bile into feces as metabolites).
Fecal (90%) as unchanged drug and metabolites; renal (<10%)
Category C
Category C
Anthelmintic
Anthelmintic